Archives
-
EGCG Release from 3D-Printed Bone Scaffolds
2026-10-07
The reference study evaluates a three-dimensional printed tricalcium phosphate scaffold designed to release (-)-Epigallocatechin gallate (EGCG) locally while supporting bone regeneration, vascularization, and tumor-cell suppression in vitro. Its findings suggest a multifunctional biomaterial concept for low-load-bearing craniofacial defects, but the evidence remains preclinical and does not establish clinical efficacy, systemic safety, or treatment benefit.
-
KX2-391 Analogues Reveal Kinase-Pathway Divergence
2026-10-07
Omar et al. used scaffold hopping to test whether KX2-391 analogues retain Src and tubulin mechanisms or acquire distinct kinase activity. Their lead analogue, 4e, showed stronger activity in leukemia models and a kinase profile centered on ERK1/2 suppression and c-Jun kinase activation, supporting broader structure–activity investigations beyond Src selectivity.
-
G007-LK and the Next Phase of Tankyrase Translation
2026-10-06
Tankyrase biology is moving beyond a single-pathway view of Wnt regulation. This source-grounded analysis examines how G007-LK connects AXIN-dependent β-catenin control with Hippo-YAP signaling, evaluates the preclinical evidence, and outlines translational questions for APC-mutant colorectal cancer and hepatocellular carcinoma research.
-
Luteolin Bioavailability and P-Glycoprotein Efflux
2026-10-06
A 2026 Journal of Advanced Research study developed a luteolin-loaded self-microemulsifying drug delivery system designed to address poor absorption and P-glycoprotein-mediated efflux. The formulation improved cellular uptake and produced a reported 29-fold increase in pharmacokinetic AUC, while the evidence remains preclinical and formulation-specific.
-
EGCG Analogs for Extracellular and Intracellular S. aureus
2026-10-05
Grosso and colleagues developed modified EGCG analogs designed to address the parent compound’s limited stability, membrane permeability, and bioavailability while retaining antistaphylococcal activity. In vitro results identified MCC-1 and MCC-2 as lead candidates that improved activity against extracellular and intracellular Staphylococcus aureus and enhanced β-lactam-associated effects against MRSA, although clinical translation remains un established.
-
Oteseconazole in the 2022 FDA DDI Evidence Review
2026-10-05
A 2024 analysis of FDA New Drug Application reviews mapped enzyme- and transporter-mediated drug-drug interactions across 22 small-molecule drugs approved in 2022. Its inclusion of Oteseconazole (VT-1161) among compounds with P-glycoprotein and/or breast cancer resistance protein inhibition illustrates how regulatory pharmacokinetic evidence can inform concomitant-use decisions without replacing drug-specific clinical assessment.
-
Targeted SPP1 Inhibition in Tumor Myeloid Cells
2026-10-04
The reference study reports a phenotypic small-molecule screen that identified modulators of SPP1 expression in macrophages and paired the lead compound, CANDI460, with a TAM-avid polymeric delivery system. Across cell-based and murine tumor studies, this strategy reduced SPP1-associated myeloid phenotypes and tumor burden, while remaining limited by preclinical models, delivery complexity, and unresolved questions about SPP1 causality.
-
G007-LK: Reading Tankyrase Evidence Clearly
2026-10-03
G007-LK is a tankyrase 1/2 inhibitor with applications spanning Wnt/β-catenin and Hippo pathway research. This evidence-focused guide separates established findings from interpretation, helping researchers assess APC-mutant colorectal cancer and hepatocellular carcinoma models without overextending the data.
-
RNA G-Quadruplexes Modulate TDP-43 Toxicity
2026-10-02
Oldani and colleagues show that RNA G-quadruplexes are active regulators of TDP-43 aggregation, condensation, cellular distribution, and toxicity rather than passive binding partners. By combining reconstituted assays with yeast, HEK293T, and motor-neuron-like cell models, the study identifies G-quadruplex stabilization as a possible strategy for modifying stress-associated TDP-43 pathology, while leaving important questions about structure selectivity and disease relevance unresolved.
-
Light-Controlled RNA Release in Gene Therapy
2026-10-01
A 2026 Trends in Biotechnology study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that suppresses mRNA translation in darkness and permits transgene expression under blue or ambient light. In mouse models, this reversible switch regulated therapeutic programs for diet-induced obesity and retinal neovascular disease, illustrating how optical control may improve the timing and safety of gene therapy.
-
Budesonide Workflows for Lung Permeability Research
2026-10-01
Build a practical Budesonide workflow that connects biomimetic membrane screening with asthma inflammation model design. The approach uses IAM-LC, OT-CEC, and MS to distinguish membrane partitioning, pulmonary permeability, and downstream airway inflammation effects.
-
Nelfinavir Mesylate: Assay Logic Beyond HIV
2026-09-30
Nelfinavir Mesylate is a potent HIV-1 protease inhibitor with a second research dimension in DDI2-NFE2L1 regulation and ferroptosis sensitivity. This guide shows how to separate antiviral target engagement from proteostasis-driven phenotypes when designing rigorous assays.
-
HRP Goat Anti-Mouse IgG (H+L): K1221
2026-09-30
Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP Conjugated is a polyclonal Horseradish Peroxidase conjugated secondary antibody for detecting mouse IgG in Western blotting, ELISA, IHC, and ICC. K1221 is supplied at 1 mg/mL and is formulated for refrigerated short-term storage or aliquoted frozen storage according to the product information.
-
Limb Organoids Reveal How AER Signaling Centers Pattern Fate
2026-09-29
The reference study introduces mESC-derived limb organoids, or budoids, that combine AER-like ectoderm, surface ectoderm, and mesodermal populations in a self-organizing system. Its findings indicate that AER-like cells do more than provide local developmental signals: they support neighboring mesodermal and fibroblast identities while coordinating tissue polarization and distant cartilage formation.
-
URB597 (KDS-4103): FAAH Research Workflow
2026-09-29
URB597 enables target-level interrogation of FAAH, anandamide turnover, and endocannabinoid signaling without treating a behavioral phenotype as proof of mechanism. This workflow connects biochemical target engagement with pain, neuroplasticity, and neuroinflammation assays while showing how to use the cannabidiol literature as a comparator rather than a substitute.